Drug Profile
Research programme: heparin derivatives - Dilafor
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Dilafor
- Class Heparins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Sweden
- 10 Sep 2009 Research is ongoing in Sweden